Atorvastatin induced liver injury: A Case Series

Atorvastatin is the most widely used statin for the prevention and treatment of cardiovascular disease. It belongs to the class of drugs called HMG-CoA reductase inhibitors. One of the most significant side effects of statins is liver injury. Liver injury as evidenced by elevation in liver enzymes o...

Full description

Saved in:
Bibliographic Details
Published in:Research journal of pharmacy and technology 2022-08, Vol.15 (8), p.3507-3510
Main Authors: Sreenivasan, Anjana, KS, Lekshmipriya, Vijayan, Meenu, G Pai, Praveen
Format: Article
Language:English
Subjects:
Asymptomatic
Cardiovascular disease
Chronic illnesses
Coronary vessels
Cytochrome
Enzymes
Hypertension
Laboratories
Liver
Mortality
Patients
Phosphatase
Statins
Transplants & implants
Vein & artery diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atorvastatin is the most widely used statin for the prevention and treatment of cardiovascular disease. It belongs to the class of drugs called HMG-CoA reductase inhibitors. One of the most significant side effects of statins is liver injury. Liver injury as evidenced by elevation in liver enzymes occurs in some patients treated with atorvastatin 10mg to 80mg. Therefore, Liver function tests (LFTs) need to be assessed before initiating atorvastatin therapy and to be repeated thereafter. Here we discuss three cases of liver enzyme elevations within 24hrs of atorvastatin treatment. Liver enzymes were completely returned to baseline after discontinuing the therapy. The risk factors of atorvastatin induced liver injury are increased age, chronic diseases, and coadministration of drugs metabolised by Cytochrome P450 3A (CYP3A) enzyme.
ISSN:0974-3618
0974-360X
0974-306X
DOI:10.52711/0974-360X.2022.00588